incretin hormone glp-1 is released from the small intestine after meal ingestion and Physiology of the incretin system.

Exenatide delays gastric emptying in patients with type 2 diabetes mellitus but not in those with gastroparetic conditions

However, the degree of appetite suppression with these medications may increase the risk if diet is not structured intentionally

GLP-1 medications may not be appropriate for everyone and can carry risks and side effects

At Teneo, we bring a unique set of skills that combines our healthcare and life sciences expertise with specialist capabilities in areas such as (but not limited to) demand modelling, strategy design, strategic communications and government affairs to help management and investors understand and navigate the impact that the growing demand for GLP-1RAs could have on their businesses

Exosome and growth-factor therapies derived from mesenchymal stem cells, which are being studied for their ability to stimulate dermal papilla cells, activate hair follicle stem cells, and promote local angiogenesis